- Home
- TLRY vs SGP Comparison
TLRY vs SGP Comparison
Compare TLRY & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | SGP |
|---|---|---|
| Founded | N/A | 2019 |
| Country | Canada | United States |
| Employees | N/A | 65 |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 650.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLRY | SGP |
|---|---|---|
| Price | $4.64 | $21.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $72.33 | $45.00 |
| AVG Volume (30 Days) | ★ 3.4M | 67.3K |
| Earning Date | 04-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.79 | N/A |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $17.06 |
| 52 Week High | $15.70 | $30.56 |
Technical Indicators
Market Signals| Indicator | TLRY | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 55.65 |
| Support Level | $1.14 | $17.33 |
| Resistance Level | $5.71 | $25.83 |
| Average True Range (ATR) | 0.25 | 1.17 |
| MACD | -0.01 | 0.38 |
| Stochastic Oscillator | 15.71 | 90.43 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.